New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
NCT ID: NCT04481204
Last Updated: 2025-10-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
105 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-04-18
Study Completion Date
2027-04-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a phase II study using the Bayesian platform design. There are three clinical stage groups of localized pancreatic cancer: resectable, borderline resectable, and locally advanced disease. Each stage group will have a defined standard of care chemotherapy regimen for a control arm, serving as a basis of comparison. Each group may have one or more experimental arms. Experimental arms may be added to the platform over time, and the effects of the experimental treatments will be tested against the controls for each group.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
NCT04233866
Metastatic Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8
ACTIVE_NOT_RECRUITING
PHASE2
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
NCT04940286
Borderline Resectable Pancreatic Adenocarcinoma
Resectable Pancreatic Adenocarcinoma
Stage IA Pancreatic Cancer AJCC v8
+3 more
ACTIVE_NOT_RECRUITING
PHASE2
Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
NCT00323583
Adenocarincoma of Pancreas
Stage III Pancreatic Cancer
Stage IVA Pancreatic Cancer
+1 more
UNKNOWN
PHASE2
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
NCT05132504
Pancreatic Ductal Adenocarcinoma
RECRUITING
PHASE2
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
NCT01660711
Pancreatic Adenocarcinoma
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. To estimate major pathological response rate. (Resectable and borderline resectable groups \[treatment naive or previously treated\]) II. To estimate 6-month disease control rate. (Locally advanced groups \[treatment naive or previously treated\])
SECONDARY OBJECTIVES:
I. To measure progression free survival and overall survival. (Resectable and borderline resectable groups \[treatment naive or previously treated\]) II. To measure progression free survival and overall survival. (Locally advanced groups \[treatment naive or previously treated\])
EXPLORATORY OBJECTIVES:
I. To benchmark tissue acquisition protocols for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) analysis in pancreatic ductal adenocarcinoma (PDAC).
II. To demonstrate concordance of cell free DNA detected mutations to those detected in the tumor-derived DNA in PDAC.
III. To demonstrate response through exosome and circulating tumor DNA. IV. To demonstrate response through the quantification of the immune activation by analyzing T and B cells, peripheral blood mononuclear cells, and tissue biopsies.
V. To derive organoids from human PDAC and measure drug response in vitro. VI. To analyze the tumor microenvironment through immunohistochemistry (IHC) and hypoxia staining.
VII. To associate prognosis of patients with baseline and follow-up quantitative computed tomography (CT) image based analysis.
VIII. To associate clinical and pathological outcomes of patients with changes in radiomic measurements.
IX. To correlate quality of life for patients on standard and experimental therapies with laboratory, radiological, pathological, and clinical characteristics.
OUTLINE:Patients are assigned to different groups, and each group has a control arm. Within each group, the patient will be randomized to the appropriate control or an experimental arm. The control arms for the groups are:
Control arm for Group I (Treatment-naive resectable PDAC): Patients receive fluorouracil, irinotecan, leucovorin, and oxaliplatin (mFOLFIRINOX) for 3 months before and after surgery in the absence of disease progression or unacceptable toxicity.
Control arm for Group II (Previously-treated resectable PDAC): Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for up to 4 months in the absence of disease progression or unacceptable toxicity.
Control arm for Group III (Treatment-naive borderline resectable PDAC): Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
Control arm for Group IV (Previously-treated borderline resectable PDAC): Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
Control arm for Group V (Treatment-naive locally advanced PDAC): Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
Control arm for Group VI (Previously-treated locally advanced PDAC): Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
After completion of study treatment, patients are followed up every 16 weeks.
I. To estimate major pathological response rate. (Resectable and borderline resectable groups \[treatment naive or previously treated\]) II. To estimate 6-month disease control rate. (Locally advanced groups \[treatment naive or previously treated\])
SECONDARY OBJECTIVES:
I. To measure progression free survival and overall survival. (Resectable and borderline resectable groups \[treatment naive or previously treated\]) II. To measure progression free survival and overall survival. (Locally advanced groups \[treatment naive or previously treated\])
EXPLORATORY OBJECTIVES:
I. To benchmark tissue acquisition protocols for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) analysis in pancreatic ductal adenocarcinoma (PDAC).
II. To demonstrate concordance of cell free DNA detected mutations to those detected in the tumor-derived DNA in PDAC.
III. To demonstrate response through exosome and circulating tumor DNA. IV. To demonstrate response through the quantification of the immune activation by analyzing T and B cells, peripheral blood mononuclear cells, and tissue biopsies.
V. To derive organoids from human PDAC and measure drug response in vitro. VI. To analyze the tumor microenvironment through immunohistochemistry (IHC) and hypoxia staining.
VII. To associate prognosis of patients with baseline and follow-up quantitative computed tomography (CT) image based analysis.
VIII. To associate clinical and pathological outcomes of patients with changes in radiomic measurements.
IX. To correlate quality of life for patients on standard and experimental therapies with laboratory, radiological, pathological, and clinical characteristics.
OUTLINE:Patients are assigned to different groups, and each group has a control arm. Within each group, the patient will be randomized to the appropriate control or an experimental arm. The control arms for the groups are:
Control arm for Group I (Treatment-naive resectable PDAC): Patients receive fluorouracil, irinotecan, leucovorin, and oxaliplatin (mFOLFIRINOX) for 3 months before and after surgery in the absence of disease progression or unacceptable toxicity.
Control arm for Group II (Previously-treated resectable PDAC): Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for up to 4 months in the absence of disease progression or unacceptable toxicity.
Control arm for Group III (Treatment-naive borderline resectable PDAC): Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
Control arm for Group IV (Previously-treated borderline resectable PDAC): Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
Control arm for Group V (Treatment-naive locally advanced PDAC): Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
Control arm for Group VI (Previously-treated locally advanced PDAC): Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
After completion of study treatment, patients are followed up every 16 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Borderline Resectable Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control arm GroupI(mFOLFIRINOX)
Patients receive mFOLFIRINOX for 3 months before and after surgery in the absence of disease progression or unacceptable toxicity.
Group Type
ACTIVE_COMPARATOR
Fluorouracil
Intervention Type
DRUG
Given IV
Irinotecan
Intervention Type
DRUG
Given IV
Leucovorin
Intervention Type
DRUG
Given IV
Oxaliplatin
Intervention Type
DRUG
Given IV
Control arm GroupII(chemotherapy, FOLFIRINOX)
Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for up to 4 months in the absence of disease progression or unacceptable toxicity.
Group Type
ACTIVE_COMPARATOR
Cisplatin
Intervention Type
DRUG
Given IV
Fluorouracil
Intervention Type
DRUG
Given IV
Gemcitabine
Intervention Type
DRUG
Given IV
Irinotecan
Intervention Type
DRUG
Given IV
Leucovorin
Intervention Type
DRUG
Given IV
Nab-paclitaxel
Intervention Type
DRUG
Given IV
Oxaliplatin
Intervention Type
DRUG
Given IV
Control arm GroupIII(FOLFIRINOX, radiation therapy)
Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
Group Type
ACTIVE_COMPARATOR
Fluorouracil
Intervention Type
DRUG
Given IV
Irinotecan
Intervention Type
DRUG
Given IV
Leucovorin
Intervention Type
DRUG
Given IV
Oxaliplatin
Intervention Type
DRUG
Given IV
Radiation Therapy
Intervention Type
RADIATION
Undergo RT
Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)
Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
Group Type
ACTIVE_COMPARATOR
Cisplatin
Intervention Type
DRUG
Given IV
Fluorouracil
Intervention Type
DRUG
Given IV
Gemcitabine
Intervention Type
DRUG
Given IV
Irinotecan
Intervention Type
DRUG
Given IV
Leucovorin
Intervention Type
DRUG
Given IV
Nab-paclitaxel
Intervention Type
DRUG
Given IV
Oxaliplatin
Intervention Type
DRUG
Given IV
Radiation Therapy
Intervention Type
RADIATION
Undergo RT
Control arm GroupV(FOLFIRINOX, radiation therapy)
Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors
Group Type
ACTIVE_COMPARATOR
Fluorouracil
Intervention Type
DRUG
Given IV
Irinotecan
Intervention Type
DRUG
Given IV
Leucovorin
Intervention Type
DRUG
Given IV
Oxaliplatin
Intervention Type
DRUG
Given IV
Radiation Therapy
Intervention Type
RADIATION
Undergo RT
Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)
Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors
Group Type
ACTIVE_COMPARATOR
Cisplatin
Intervention Type
DRUG
Given IV
Fluorouracil
Intervention Type
DRUG
Given IV
Gemcitabine
Intervention Type
DRUG
Given IV
Irinotecan
Intervention Type
DRUG
Given IV
Leucovorin
Intervention Type
DRUG
Given IV
Nab-paclitaxel
Intervention Type
DRUG
Given IV
Oxaliplatin
Intervention Type
DRUG
Given IV
Radiation Therapy
Intervention Type
RADIATION
Undergo RT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cisplatin
Given IV
Intervention Type
DRUG
Fluorouracil
Given IV
Intervention Type
DRUG
Gemcitabine
Given IV
Intervention Type
DRUG
Irinotecan
Given IV
Intervention Type
DRUG
Leucovorin
Given IV
Intervention Type
DRUG
Nab-paclitaxel
Given IV
Intervention Type
DRUG
Oxaliplatin
Given IV
Intervention Type
DRUG
Radiation Therapy
Undergo RT
Intervention Type
RADIATION
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Abiplatin
Blastolem
Briplatin
CDDP
Cis-diammine-dichloroplatinum
Cis-diamminedichloridoplatinum
Cis-diamminedichloro Platinum (II)
Cis-diamminedichloroplatinum
Cis-dichloroammine Platinum (II)
Cis-platinous Diamine Dichloride
Cis-platinum
Cis-platinum II
Cis-platinum II Diamine Dichloride
Cismaplat
Cisplatina
Cisplatinum
Cisplatyl
Citoplatino
Citosin
Cysplatyna
DDP
Lederplatin
Metaplatin
Neoplatin
Peyrone''s Chloride
Peyrone''s Salt
Placis
Plastistil
Platamine
Platiblastin
Platiblastin-S
Platinex
Platinol
Platinol- AQ
Platinol-AQ
Platinol-AQ VHA Plus
Platinoxan
Platinum
Platinum Diamminodichloride
Platiran
Platistin
Platosin
5 Fluorouracil
5 Fluorouracilum
5 FU
5-Fluoro-2,4(1H, 3H)-pyrimidinedione
5-Fluorouracil
5-Fluracil
5-Fu
5FU
AccuSite
Carac
Fluoro Uracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluril
Fluroblastin
Ribofluor
Ro 2-9757
Ro-2-9757
dFdC
dFdCyd
Difluorodeoxycytidine
Folinic acid
ABI 007
ABI-007
Abraxane
Albumin-bound Paclitaxel
Albumin-Stabilized Nanoparticle Paclitaxel
Nanoparticle Albumin-bound Paclitaxel
Nanoparticle Paclitaxel
Paclitaxel Albumin
paclitaxel albumin-stabilized nanoparticle formulation
Protein-bound Paclitaxel
1-OHP
Ai Heng
Aiheng
Dacotin
Dacplat
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
JM-83
Oxalatoplatin
Oxalatoplatinum
RP 54780
RP-54780
SR-96669
Cancer Radiotherapy
Irradiate
Irradiated
Irradiation
Radiation
Radiation Therapy, NOS
Radiotherapeutics
Radiotherapy
RT
Therapy, Radiation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Pathologically proven adenocarcinoma of the pancreas by cytology or biopsy
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Confirmation of clinical stage of resectable
* TREATMENT NAIVE RESECTABLE PDAC COHORT: No prior chemotherapy or radiation therapy for PDAC
* TREATMENT NAIVE RESECTABLE PDAC COHORT: No current use of immunosuppressive medication
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Not pregnant and not nursing, for women of childbearing potential, a negative urine or blood pregnancy test done =\< 7 days prior to registration is required
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Life expectancy greater than 6 months
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Platelet count \>= 100,000/mm\^3
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Creatinine =\< 1.5 x upper limit of normal (ULN)
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Calculated (Calc.) creatinine clearance \> 45 mL/min
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Total bilirubin =\< 2.0 mg/dL
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal (ULN)
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Hemoglobin \>= 8.0 mg/dL
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Pathologically proven adenocarcinoma of the pancreas by cytology or biopsy
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Confirmation of clinical stage of resectable
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Prior chemotherapy for PDAC is allowed, as long as the regimen is considered a standard regimen for PDAC (e.g., gemcitabine, gemcitabine-cisplatin, gemcitabine/nab-paclitaxel, gemcitabine/capecitabine, FOLFIRINOX). This should be discussed with the study principal investigators (PIs) prior to enrollment to ensure the regimen for a given patient is acceptable
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: No current use of immunosuppressive medication
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Not pregnant and not nursing, For women of childbearing potential, a negative urine or blood pregnancy test done ≤ 7 days prior to registration is required
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Life expectancy greater than 6 months
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: ECOG performance status 0 or 1
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Platelet count \>= 100,000/mm\^3
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Creatinine =\< 1.5 x upper limit of normal (ULN)
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Calc. creatinine clearance \> 45 mL/min
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Total bilirubin =\< 2.0 mg/dL
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: AST/ALT =\< 2.5 x upper limit of normal (ULN)
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Hemoglobin \>= 8.0 mg/dL
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Pathologically proven adenocarcinoma of the pancreas by cytology or biopsy
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Confirmation of clinical stage of borderline resectable
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: No prior chemotherapy or radiation therapy for PDAC
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: No current use of immunosuppressive medication
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Not pregnant and not nursing, For women of childbearing potential, a negative urine or blood pregnancy test done ≤ 7 days prior to registration is required
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Life expectancy greater than 6 months
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: ECOG performance status 0 or 1
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Platelet count \>= 100,000/mm\^3
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Creatinine =\< 1.5 x upper limit of normal (ULN)
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Calc. creatinine clearance \> 45 mL/min
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Total bilirubin =\< 2.0 mg/dL
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: AST/ALT =\< 2.5 x upper limit of normal (ULN)
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Hemoglobin \>= 8.0 mg/dL
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Pathologically proven adenocarcinoma of the pancreas by cytology or biopsy
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Confirmation of clinical stage of borderline resectable
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Prior chemotherapy for PDAC is allowed, as long as the regimen is considered a standard regimen for PDAC (e.g., gemcitabine, gemcitabine-cisplatin, gemcitabine/nab-paclitaxel, gemcitabine/capecitabine, FOLFIRINOX). This should be discussed with the study PIs prior to enrollment to ensure the regimen for a given patient is acceptable
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: No current use of immunosuppressive medication
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Not pregnant and not nursing, For women of childbearing potential, a negative urine or blood pregnancy test done =\< 7 days prior to registration is required
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Life expectancy greater than 6 months
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: ECOG performance status 0 or 1
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Platelet count \>= 100,000/mm\^3
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Creatinine =\< 1.5 x upper limit of normal (ULN)
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Calc. creatinine clearance \> 45 mL/min
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Total bilirubin =\< 2.0 mg/dL
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: AST/ALT =\< 2.5 x upper limit of normal (ULN)
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Hemoglobin \>= 8.0 mg/dL
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Pathologically proven adenocarcinoma of the pancreas by cytology or biopsy
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Confirmation of clinical stage of locally advanced
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: No prior chemotherapy or radiation therapy for PDAC
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Pregnancy and Nursing Status: Not pregnant and not nursing, For women of childbearing potential, a negative urine or blood pregnancy test done ≤ 7 days prior to registration is required
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Life expectancy greater than 6 months
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: ECOG performance status 0 or 1
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Platelet count \>= 100,000/mm\^3
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Creatinine =\< 1.5 x upper limit of normal (ULN)
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Calc. creatinine clearance \> 45 mL/min
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Total bilirubin =\< 2.0 mg/dL
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: AST/ALT =\< 2.5 x upper limit of normal (ULN)
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Hemoglobin \>= 8.0 mg/dL
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Pathologically proven adenocarcinoma of the pancreas by cytology or biopsy
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Confirmation of clinical stage of locally advanced
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Prior chemotherapy for PDAC is allowed, as long as the regimen is considered a standard regimen for PDAC (e.g., gemcitabine, gemcitabine-cisplatin, gemcitabine/nab-paclitaxel, gemcitabine/capecitabine, FOLFIRINOX). This should be discussed with the study PIs prior to enrollment to ensure the regimen for a given patient is acceptable
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: No current use of immunosuppressive medication
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Not pregnant and not nursing, For women of childbearing potential, a negative urine or blood pregnancy test done =\< 7 days prior to registration is required
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Life expectancy greater than 6 months
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: ECOG performance status 0 or 1
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Platelet count \>= 100,000/mm\^3
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Creatinine =\< 1.5 x upper limit of normal (ULN)
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Calc. creatinine clearance \> 45 mL/min
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Total bilirubin =\< 2.0 mg/dL
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: AST/ALT =\< 2.5 x upper limit of normal (ULN)
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Hemoglobin \>= 8.0 mg/dL
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Confirmation of clinical stage of resectable
* TREATMENT NAIVE RESECTABLE PDAC COHORT: No prior chemotherapy or radiation therapy for PDAC
* TREATMENT NAIVE RESECTABLE PDAC COHORT: No current use of immunosuppressive medication
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Not pregnant and not nursing, for women of childbearing potential, a negative urine or blood pregnancy test done =\< 7 days prior to registration is required
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Life expectancy greater than 6 months
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Platelet count \>= 100,000/mm\^3
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Creatinine =\< 1.5 x upper limit of normal (ULN)
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Calculated (Calc.) creatinine clearance \> 45 mL/min
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Total bilirubin =\< 2.0 mg/dL
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal (ULN)
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Hemoglobin \>= 8.0 mg/dL
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Pathologically proven adenocarcinoma of the pancreas by cytology or biopsy
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Confirmation of clinical stage of resectable
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Prior chemotherapy for PDAC is allowed, as long as the regimen is considered a standard regimen for PDAC (e.g., gemcitabine, gemcitabine-cisplatin, gemcitabine/nab-paclitaxel, gemcitabine/capecitabine, FOLFIRINOX). This should be discussed with the study principal investigators (PIs) prior to enrollment to ensure the regimen for a given patient is acceptable
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: No current use of immunosuppressive medication
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Not pregnant and not nursing, For women of childbearing potential, a negative urine or blood pregnancy test done ≤ 7 days prior to registration is required
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Life expectancy greater than 6 months
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: ECOG performance status 0 or 1
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Platelet count \>= 100,000/mm\^3
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Creatinine =\< 1.5 x upper limit of normal (ULN)
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Calc. creatinine clearance \> 45 mL/min
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Total bilirubin =\< 2.0 mg/dL
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: AST/ALT =\< 2.5 x upper limit of normal (ULN)
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Hemoglobin \>= 8.0 mg/dL
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Pathologically proven adenocarcinoma of the pancreas by cytology or biopsy
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Confirmation of clinical stage of borderline resectable
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: No prior chemotherapy or radiation therapy for PDAC
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: No current use of immunosuppressive medication
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Not pregnant and not nursing, For women of childbearing potential, a negative urine or blood pregnancy test done ≤ 7 days prior to registration is required
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Life expectancy greater than 6 months
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: ECOG performance status 0 or 1
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Platelet count \>= 100,000/mm\^3
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Creatinine =\< 1.5 x upper limit of normal (ULN)
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Calc. creatinine clearance \> 45 mL/min
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Total bilirubin =\< 2.0 mg/dL
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: AST/ALT =\< 2.5 x upper limit of normal (ULN)
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Hemoglobin \>= 8.0 mg/dL
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Pathologically proven adenocarcinoma of the pancreas by cytology or biopsy
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Confirmation of clinical stage of borderline resectable
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Prior chemotherapy for PDAC is allowed, as long as the regimen is considered a standard regimen for PDAC (e.g., gemcitabine, gemcitabine-cisplatin, gemcitabine/nab-paclitaxel, gemcitabine/capecitabine, FOLFIRINOX). This should be discussed with the study PIs prior to enrollment to ensure the regimen for a given patient is acceptable
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: No current use of immunosuppressive medication
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Not pregnant and not nursing, For women of childbearing potential, a negative urine or blood pregnancy test done =\< 7 days prior to registration is required
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Life expectancy greater than 6 months
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: ECOG performance status 0 or 1
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Platelet count \>= 100,000/mm\^3
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Creatinine =\< 1.5 x upper limit of normal (ULN)
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Calc. creatinine clearance \> 45 mL/min
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Total bilirubin =\< 2.0 mg/dL
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: AST/ALT =\< 2.5 x upper limit of normal (ULN)
* PREVIOUSLY TREATED BORDERLINE RESECTABLE PDAC COHORT: Hemoglobin \>= 8.0 mg/dL
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Pathologically proven adenocarcinoma of the pancreas by cytology or biopsy
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Confirmation of clinical stage of locally advanced
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: No prior chemotherapy or radiation therapy for PDAC
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Pregnancy and Nursing Status: Not pregnant and not nursing, For women of childbearing potential, a negative urine or blood pregnancy test done ≤ 7 days prior to registration is required
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Life expectancy greater than 6 months
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: ECOG performance status 0 or 1
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Platelet count \>= 100,000/mm\^3
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Creatinine =\< 1.5 x upper limit of normal (ULN)
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Calc. creatinine clearance \> 45 mL/min
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Total bilirubin =\< 2.0 mg/dL
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: AST/ALT =\< 2.5 x upper limit of normal (ULN)
* TREATMENT NAIVE LOCALLY ADVANCED PDAC COHORT: Hemoglobin \>= 8.0 mg/dL
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Pathologically proven adenocarcinoma of the pancreas by cytology or biopsy
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Confirmation of clinical stage of locally advanced
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Prior chemotherapy for PDAC is allowed, as long as the regimen is considered a standard regimen for PDAC (e.g., gemcitabine, gemcitabine-cisplatin, gemcitabine/nab-paclitaxel, gemcitabine/capecitabine, FOLFIRINOX). This should be discussed with the study PIs prior to enrollment to ensure the regimen for a given patient is acceptable
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: No current use of immunosuppressive medication
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Not pregnant and not nursing, For women of childbearing potential, a negative urine or blood pregnancy test done =\< 7 days prior to registration is required
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Life expectancy greater than 6 months
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: ECOG performance status 0 or 1
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Platelet count \>= 100,000/mm\^3
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Creatinine =\< 1.5 x upper limit of normal (ULN)
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Calc. creatinine clearance \> 45 mL/min
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Total bilirubin =\< 2.0 mg/dL
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: AST/ALT =\< 2.5 x upper limit of normal (ULN)
* PREVIOUSLY TREATED LOCALLY ADVANCED PDAC COHORT: Hemoglobin \>= 8.0 mg/dL
Exclusion Criteria
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Previous treatment for PDAC with chemotherapy or radiation
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Active malignancy, except basal cell carcinoma
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Staging other than resectable PDAC
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Known uncontrolled (grade \>=2) or active gastric or duodenal ulcer disease within 30 days of enrollment
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Prior surgical resection of pancreatic tumor
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Known contraindication to iodine-based or gadolinium-based intravenous (IV) contrast
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second or third degree atrioventricular heart block without a permanent pacemaker in place)
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Class III or IV congestive heart failure as defined by the New York Heart Association functional classification system \< 6 months prior to screening
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Known active, uncontrolled (high viral load) human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
* Patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Female patients who are pregnant of breastfeeding
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of \< 1% per year when used consistently and correctly
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Have significant psychiatric, social, or medical condition(s) that could increase the subject's risk, interfere with protocol adherence, or affect the subject's ability to give informed consent
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: The patient is treatment naive
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: The patient previously received radiation to the abdomen for any reason
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Active malignancy, except basal cell carcinoma
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Staging other than resectable PDAC at the time of diagnosis
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Receiving any approved or investigational anti-neoplastic agent other than the chemotherapies specified in this protocol
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Known uncontrolled (grade \>= 2) or active gastric or duodenal ulcer disease within 30 days of enrollment
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Prior surgical resection of pancreatic tumor
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Known contraindication to iodine-based or gadolinium-based IV contrast
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second or third degree atrioventricular heart block without a permanent pacemaker in place)
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Class III or IV congestive heart failure as defined by the New York Heart Association functional classification system \< 6 months prior to screening
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Known active, uncontrolled (high viral load) HIV, hepatitis B or hepatitis C infection
* Patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Female patients who are pregnant of breastfeeding
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of \< 1% per year when used consistently and correctly
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Have significant psychiatric, social, or medical condition(s) that could increase the subject's risk, interfere with protocol adherence, or affect the subject's ability to give informed consent
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Previous treatment for PDAC with chemotherapy or radiation
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Active malignancy, except basal cell carcinoma
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Staging other than borderline resectable PDAC
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Known uncontrolled (grade \>= 2) or active gastric or duodenal ulcer disease within 30 days of enrollment
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Prior surgical resection of pancreatic tumor
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Known contraindication to iodine-based or gadolinium-based IV contrast
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second or third degree atrioventricular heart block without a permanent pacemaker in place)
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Class III or IV congestive hea
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Active malignancy, except basal cell carcinoma
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Staging other than resectable PDAC
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Known uncontrolled (grade \>=2) or active gastric or duodenal ulcer disease within 30 days of enrollment
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Prior surgical resection of pancreatic tumor
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Known contraindication to iodine-based or gadolinium-based intravenous (IV) contrast
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second or third degree atrioventricular heart block without a permanent pacemaker in place)
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Class III or IV congestive heart failure as defined by the New York Heart Association functional classification system \< 6 months prior to screening
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Known active, uncontrolled (high viral load) human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
* Patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Female patients who are pregnant of breastfeeding
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of \< 1% per year when used consistently and correctly
* TREATMENT NAIVE RESECTABLE PDAC COHORT: Have significant psychiatric, social, or medical condition(s) that could increase the subject's risk, interfere with protocol adherence, or affect the subject's ability to give informed consent
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: The patient is treatment naive
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: The patient previously received radiation to the abdomen for any reason
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Active malignancy, except basal cell carcinoma
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Staging other than resectable PDAC at the time of diagnosis
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Receiving any approved or investigational anti-neoplastic agent other than the chemotherapies specified in this protocol
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Known uncontrolled (grade \>= 2) or active gastric or duodenal ulcer disease within 30 days of enrollment
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Prior surgical resection of pancreatic tumor
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Known contraindication to iodine-based or gadolinium-based IV contrast
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second or third degree atrioventricular heart block without a permanent pacemaker in place)
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Class III or IV congestive heart failure as defined by the New York Heart Association functional classification system \< 6 months prior to screening
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Known active, uncontrolled (high viral load) HIV, hepatitis B or hepatitis C infection
* Patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Female patients who are pregnant of breastfeeding
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of \< 1% per year when used consistently and correctly
* PREVIOUSLY TREATED RESECTABLE PDAC COHORT: Have significant psychiatric, social, or medical condition(s) that could increase the subject's risk, interfere with protocol adherence, or affect the subject's ability to give informed consent
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Previous treatment for PDAC with chemotherapy or radiation
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Active malignancy, except basal cell carcinoma
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Staging other than borderline resectable PDAC
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Known uncontrolled (grade \>= 2) or active gastric or duodenal ulcer disease within 30 days of enrollment
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Prior surgical resection of pancreatic tumor
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Known contraindication to iodine-based or gadolinium-based IV contrast
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second or third degree atrioventricular heart block without a permanent pacemaker in place)
* TREATMENT NAIVE BORDERLINE RESECTABLE PDAC COHORT: Class III or IV congestive hea
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
M.D. Anderson Cancer Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eugene J Koay
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
M D Anderson Cancer Center
Houston, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Douglas JE, Liu S, Ma J, Wolff RA, Pant S, Maitra A, Tamm EP, Bhosale P, Katz MHG, Varadhachary GR, Koay EJ. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. BMC Cancer. 2022 Jan 3;22(1):14. doi: 10.1186/s12885-021-09095-7.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
http://www.mdanderson.org
M D Anderson Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2020-04886
Identifier Type: REGISTRY
Identifier Source: secondary_id
2020-0075
Identifier Type: OTHER
Identifier Source: secondary_id
2020-0075
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT02754726
COMPLETED
PHASE2
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
NCT02620800
COMPLETED
PHASE1
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
NCT03703063
UNKNOWN
PHASE1
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02562716
COMPLETED
PHASE2
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
NCT03970252
COMPLETED
EARLY_PHASE1
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02427841
COMPLETED
PHASE2
Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas
NCT00038701
TERMINATED
PHASE2
Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer
NCT00417287
TERMINATED
PHASE2
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
NCT02194829
COMPLETED
PHASE1/PHASE2
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
NCT05825066
RECRUITING
PHASE2
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
NCT06998940
NOT_YET_RECRUITING
PHASE3
Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma
NCT02172976
COMPLETED
PHASE2/PHASE3
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
NCT01560949
COMPLETED
PHASE2
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
NCT01488552
COMPLETED
PHASE1/PHASE2
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
NCT01821612
COMPLETED
EARLY_PHASE1
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
NCT04447092
ACTIVE_NOT_RECRUITING
PHASE2
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
NCT06423326
RECRUITING
PHASE2
Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
NCT02782182
TERMINATED
PHASE1
Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
NCT00728000
WITHDRAWN
PHASE2
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
NCT07076212
RECRUITING
PHASE2
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
NCT02336087
ACTIVE_NOT_RECRUITING
PHASE1
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
NCT01531712
TERMINATED
PHASE2
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
NCT01397019
COMPLETED
PHASE2
Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
NCT00049348
COMPLETED
PHASE2